Nucleotide substitution: T?A. A T to A transversion has occurred in the second nucleotide of the intron between exons 9 and 10. This leads to an aberrantly spliced transcript that retains the whole intron and would result in a prematurely truncated protein.
T15039153A
T?A
T to A transversion in the splice acceptor results in a retained intron and early translation termination.
Stage 12 hbs2593/Df(2R)X28 or hbs459/hbs2593 embryos have a reduction in the number of visceral muscle progenitors. hbs2593/Df(2R)X28, or hbs459/hbs2593 embryos The overall pattern or somatic muscles is normal, though there is a partial fusion block in embryos (especially around the heart). The unfused myoblasts can still extend filopodia. Mutant embryos also show a gut phenotype consisting of an enlarged first gut chamber, which pushes the dorsal muscles and heart upwards.
hbs459/hbs2593 has embryonic myoblast phenotype, enhanceable by sns[+]/snsXB3
hbs459/hbs2593 has embryonic myoblast phenotype, enhanceable by sns[+]/snsD1
hbs459/hbs2593 has embryonic myoblast phenotype, suppressible by snsXB3
hbs459/hbs2593 has embryonic midgut chamber 1 phenotype, suppressible by snsXB3
hbs459/hbs2593 has visceral muscle primordium phenotype, suppressible by snsXB3
hbs459/hbs2593 has presumptive embryonic/larval muscle system phenotype, suppressible by snsXB3
hbs2593, snsXB3 has muscle founder cell | embryonic stage phenotype, non-suppressible by Scer\GAL4Mef2.PR/sns20-5.UAS.Tag:HA
hbs2593, snsXB3 has muscle founder cell | embryonic stage phenotype, non-suppressible by hbsΔICD.UAS.Tag:HA/Scer\GAL4Mef2.PR
hbs2593 is an enhancer of muscle founder cell | embryonic stage phenotype of snsXB3
hbs2593/hbs[+] is an enhancer of interommatidial precursor cell | pupal stage P7 phenotype of rst6
hbs459/hbs2593, snsXB3/snsD1 has muscle founder cell | embryonic stage phenotype
hbs2593, snsXB3 has embryonic garland cell phenotype
hbs2593/hbs[+], rst6 has interommatidial bristle | pupal stage P7 phenotype
There is a lower number of eve-expressing DA1 founder cells, Kr-expressing DO1 founder cells, and nau-expressing VA1 founder cells in snsXB3 hbs2593 double mutant embryos than in snsXB3 embryos - these founder cells remain mononucleate in most hemi-segments.
snsXB3, hbs2593 / snsD1, hbs459 embryos have a relatively low number of eve-expressing DA1 founder cells - fewer than in snsXB3 embryos.
The limited number of unfused myoblasts in hbs2593/hbs459 embryos increases when embryos are also heterozygous for snsXB3 or snsD1.
Scer\GAL4Mef2.PR-mediated expression of sns20-5.Scer\UAS.T:Ivir\HA1 or hbsΔICD.Scer\UAS.T:Ivir\HA1 fails to rescue formation of eve-positive DA1 or Kr-positive DO1 bi- and tri-nucleate muscle precursors in snsXB3, hbs2593 double mutant embryos.
Almost 60% of garland cell nephrocytes (GCNs) remain mononucleate at early stage 16 in snsXB3 hbs2593 double mutant embryos (in contrast to wild-type embryos where 99.6% of the GCNs are binucleate at this stage). The GCNs of stage 16 snsXB3 hbs2593 double mutant embryos are disorganised, misshapen and more loosely associated than in wild-type embryos.